Picture of Spero Therapeutics logo

SPRO — Spero Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapContrarian

Spero Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

* Spero Therapeutics Inc  SPRO.OQ  reported a quarterly
adjusted
loss of 33 cents​​ per share for the quarter ended in June,
lower than the same quarter last year, when the company reported
EPS of -23 cents.  The mean expectation of three analysts for
the quarter was for a loss of 38 cents per share. Wall Street
expected results to range from -45 cents to -25 cents per share.
    * Revenue rose 275.4% to $10.20 million from a year ago;
analysts
expected $3.27 million. 
    * Spero Therapeutics Inc's reported EPS for the quarter was
a loss
of 33 cents​.
    * The company reported a quarterly loss of $17.86 million.
    * Spero Therapeutics Inc shares had risen by 0.8% this
quarter and
lost 10.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 14.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Spero
Therapeutics Inc is $7.50 
This summary was machine generated from LSEG data August 5 at
09:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.38          -0.33          Beat
 Mar. 31 2024      -0.04          -0.24          Missed
 Dec. 31 2023      -0.10          0.96           Beat
 Sep. 30 2023      -0.03          0.04           Beat

Recent news on Spero Therapeutics

See all news